Novartis is acquiring AveXis for $8.7 billion to strengthen its gene therapy unit, adding a promising but still experimental treatment targeting a fatal childhood disease.

AveXis, a small biotech based in a north Chicago suburb, is being purchased for $218 per share, or an 88 percent premium to Friday’s closing stock price, Novartis said.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • 8 billion for pre clinical
    what ARNA WORTH now?
    with 2 blockbusters in phase 3
    Entrisimod and Ralinepeg?? 12 bill–16 billion??

    as RCPT and Selexipeg

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy